ReviewPharmacology & therapeutics2020
Targeting neurotrophic factors: Novel approaches to musculoskeletal pain.
Review in Pharmacology & therapeutics, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT05570240 (The Relationship Between Chronic OA Pain and Cognition Deficits in OA Patients.), which is not on this map. Cited by 25 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
The Relationship Between Chronic OA Pain and Cognition Deficits in OA Patients.
Who cites it
25 citing papers in PubMed, 1 synthesis or guideline pooled it.
- Relative Efficacy and Safety of Tanezumab for Osteoarthritis: A Systematic Review and Meta-analysis of Randomized-Controlled Trials.The Clinical journal of pain · 2021Pooled it
- Hydrogel-based neural engineering for skin wound healing.Frontiers in cell and developmental biology · 2026Review
- Inhibition of ErbB2 mitigates secondary denervation after traumatic muscle injury.The Journal of physiology · 2025Article
- Peripheral neuronal sensitization and neurovascular remodelling in osteoarthritis pain.Nature reviews. Rheumatology · 2025Review
- Unraveling Osteoarthritis: Mechanistic Insights and Emerging Therapies Targeting Pain and Inflammation.Biomolecules · 2025Review
- Modulation of Neurturin Expression by Lumbosacral Spinal Stenosis, Lifestyle Factors, and Glycemic Dysregulation.Biomedicines · 2025Article
- Osteoarthritis.Nature reviews. Disease primers · 2025Review
- Axonopathy Underlying Amyotrophic Lateral Sclerosis: Unraveling Complex Pathways and Therapeutic Insights.Neuroscience bulletin · 2024Review
- The role of obesity and adipose tissue dysfunction in osteoarthritis pain.Nature reviews. Rheumatology · 2024Review
- Inflammation in the Peripheral Nervous System after Injury.Biomedicines · 2024Review
- Assessment of Neuropathic Pain in Erosive Hand Osteoarthritis.Journal of clinical medicine · 2024Article
- The Crosstalk between Nerves and Cancer-A Poorly Understood Phenomenon and New Possibilities.Cancers · 2024Review
- Molecular pathogenesis of OA pain: Past, present, and future.Osteoarthritis and cartilage · 2024Review
- Pain-phenotyping in osteoarthritis: Current concepts, evidence, and considerations towards a comprehensive framework for assessment and treatment.Osteoarthritis and cartilage open · 2024Review
- Pain Biomarkers in Fibromyalgia Syndrome: Current Understanding and Future Directions.International journal of molecular sciences · 2023Review
- Sex-Related Pain Behavioral Differences following Unilateral NGF Injections in a Rat Model of Low Back Pain.Biology · 2022Article
- Association of Biomarkers with Individual and Multiple Body Sites of Pain: The Johnston County Osteoarthritis Project.Journal of pain research · 2022Article
- Basic Mechanisms of Pain in Osteoarthritis: Experimental Observations and New Perspectives.Rheumatic diseases clinics of North America · 2021Review
- The role of intra-articular neuronal CCR2 receptors in knee joint pain associated with experimental osteoarthritis in mice.Arthritis research & therapy · 2021Article
- Efficacy and Safety of Medicines Targeting Neurotrophic Factors in the Management of Low Back Pain: Protocol for a Systematic Review and Meta-analysis.JMIR research protocols · 2021Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
Abstract
Chronic pain represents a substantial unmet medical need globally. In recent years, the quest for a new generation of novel, safe, mechanism-based analgesic treatments has focused on neurotrophic factors, a large group of secreted proteins that control the growth and survival of different populations of neurons, but that postnatally are involved in the genesis and maintenance of pain, with biological activity in both the periphery and the central nervous system. In this narrative review, we discuss the two families of neurotrophic proteins that have been extensively studied for their role in pain: first, the neurotrophins, nerve growth factor (NGF) and brain-derived growth factor (BDNF), and secondly, the GDNF family of ligands (GFLs). We provide an overview of the pain pathway, and the pain-producing effects of these different proteins. We summarize accumulating preclinical and clinical findings with a focus on musculoskeletal pain, and on osteoarthritis in particular, because the musculoskeletal system is the most prevalent source of chronic pain and of disability, and clinical testing of these novel agents - often biologics- is most advanced in this area.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.